NASDAQ:XOMA - XOMA Stock Price, News & Analysis

$18.79
-0.42 (-2.19 %)
(As of 09/15/2019 04:00 PM ET)
Today's Range
$18.61
Now: $18.79
$19.14
50-Day Range
$15.73
MA: $17.66
$19.07
52-Week Range
$11.02
Now: $18.79
$20.29
Volume18,234 shs
Average Volume47,655 shs
Market Capitalization$164.04 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.30 million
Book Value$2.24 per share

Profitability

Net Income$-13,340,000.00

Miscellaneous

Employees11
Market Cap$164.04 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.


XOMA (NASDAQ:XOMA) Frequently Asked Questions

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) announced its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. The biotechnology company had revenue of $0.96 million for the quarter, compared to analysts' expectations of $0.63 million. XOMA had a negative return on equity of 51.91% and a negative net margin of 72.20%. View XOMA's Earnings History.

When is XOMA's next earnings date?

XOMA is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for XOMA.

What price target have analysts set for XOMA?

3 Wall Street analysts have issued 12 month price objectives for XOMA's shares. Their predictions range from $25.00 to $30.00. On average, they anticipate XOMA's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 46.4% from the stock's current price. View Analyst Price Targets for XOMA.

What is the consensus analysts' recommendation for XOMA?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA.

What are Wall Street analysts saying about XOMA stock?

Here are some recent quotes from research analysts about XOMA stock:
  • 1. HC Wainwright analysts commented, "We project U.S. peak sales of $325M in 2026 for DSUVIA. For Zalviso, we project product launch in 1H20 (85% POS) with peak sales in 2027 of about $185M. We apply a 12.5% discount rate to both products." (4/12/2019)
  • 2. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (3/9/2019)

Has XOMA been receiving favorable news coverage?

Media coverage about XOMA stock has been trending somewhat positive on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XOMA earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for XOMA.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

Who are XOMA's key executives?

XOMA's management team includes the folowing people:
  • Mr. James R. Neal, CEO & Director (Age 63)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
  • Dr. Deepshikha Datta, Chief Bus. Officer

Who are XOMA's major shareholders?

XOMA's stock is owned by many different of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (3.10%), Fosun International Ltd (3.06%), Vanguard Group Inc. (2.76%), BlackRock Inc. (1.84%), RBF Capital LLC (1.14%) and Northern Trust Corp (0.89%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology. View Institutional Ownership Trends for XOMA.

Which institutional investors are selling XOMA stock?

XOMA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., AXA, Bank of New York Mellon Corp, Vanguard Group Inc., GSA Capital Partners LLP, Wells Fargo & Company MN, Northern Trust Corp and Fosun International Ltd. View Insider Buying and Selling for XOMA.

Which institutional investors are buying XOMA stock?

XOMA stock was bought by a variety of institutional investors in the last quarter, including RBF Capital LLC, Stonepine Capital Management LLC, Paloma Partners Management Co, Marshall Wace LLP, Morgan Stanley and Athanor Capital LP. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal and Value Fund L P Biotechnology. View Insider Buying and Selling for XOMA.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $18.79.

How big of a company is XOMA?

XOMA has a market capitalization of $164.04 million and generates $5.30 million in revenue each year. The biotechnology company earns $-13,340,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. XOMA employs 11 workers across the globe.View Additional Information About XOMA.

What is XOMA's official website?

The official website for XOMA is http://www.xoma.com/.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]


MarketBeat Community Rating for XOMA (NASDAQ XOMA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  373 (Vote Outperform)
Underperform Votes:  348 (Vote Underperform)
Total Votes:  721
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel